Safety and Efficacy of Once Weekly Subcutaneous Bortezomib in Advanced Stage AL Amyloidosis

被引：0
|
作者：
Bumma, Naresh [1 ]
Reu, Frederic J. [1 ]
Samaras, Christy [1 ]
Duong, Hien K. [1 ]
Smith, Mitchell R. [1 ]
Valent, Jason [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis
    Dorneles, Gilson
    Algeri, Ellen
    Lauterbach, Gerhard
    Pereira, Marcelo
    Fernandes, Brigida
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2024, 132 (06) : 316 - 327
  • [32] Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis
    Sachchithanantham, Sajitha
    Mahmood, Shameem
    Sayed, Rabya
    Patel, Ketna
    Fontana, Marianna
    Lane, Thirusha
    Rannigan, Lisa
    Foard, Darren
    Whelan, Carol
    Lachmann, Helen
    Gillmore, Julian D.
    Hawkins, Philip N.
    Wechalekar, Ashutosh
    BLOOD, 2013, 122 (21)
  • [33] Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
    Wechalekar, Ashutosh D.
    Lachmann, Helen J.
    Offer, Mark
    Hawkins, Philip N.
    Gillmore, Julian D.
    HAEMATOLOGICA, 2008, 93 (02) : 295 - 298
  • [34] Efficacy and safety by duration of diabetes with once weekly dulaglutide in the AWARD programme
    Gallwitz, B.
    Thieu, V.
    Pavo, I.
    Jia, N.
    Zhang, N.
    Garcia-Perez, L. -E.
    DIABETOLOGIA, 2016, 59 : S75 - S75
  • [35] The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
    Heimburger, Sebastian M.
    Bronden, Andreas
    Johansen, Nicklas J.
    Dejgaard, Thomas F.
    Vilsboll, Tina
    Knop, Filip K.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (05) : 501 - 510
  • [36] Efficacy and Safety of Bortezomib plus Dexamethasone Therapy for Refractory or Relapsed Multiple Myeloma: Once-weekly Administration of Bortezomib may Reduce the Incidence of Gastrointestinal Adverse Events
    Fukushima, Toshihiro
    Nakamura, Takuji
    Iwao, Haruka
    Nakajima, Akio
    Miki, Miyuki
    Sato, Tomomi
    Sakai, Tomoyuki
    Sawaki, Toshioki
    Fujita, Yoshimasa
    Tanaka, Masao
    Masaki, Yasufumi
    Nakajima, Hideo
    Motoo, Yoshiharu
    Umehara, Hisanori
    ANTICANCER RESEARCH, 2011, 31 (06) : 2297 - 2302
  • [37] Semaglutide once-weekly: improved efficacy with a new safety warning
    Coon, Scott A.
    Crannage, Erica F.
    Kerwin, Lara C.
    Guyton, Justinne E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (11) : 1061 - 1072
  • [38] Once-Weekly Subcutaneous Bortezomib Plus Oral Cyclophosphamide and Dexamethasone Therapy For Relapsed Or Refractory Multiple Myeloma
    Takamatsu, Yasushi
    Imamura, Yutaka
    Nakazato, Tomonori
    Uike, Naokuni
    Miyashita, Kaname
    Saburi, Yoshio
    Harada, Naoki
    Ota, Shuichi
    Imamura, Rie
    Miyamoto, Toshihiro
    BLOOD, 2013, 122 (21)
  • [39] The efficacy and safety of once-weekly, subcutaneous dulaglutide monotherapy compared to glimepiride in Asian patients with type 2 diabetes mellitus
    Wang, W.
    Huang, C. -N.
    Young, M. -C.
    Li, P.
    Gu, L.
    Yang, J.
    DIABETOLOGIA, 2015, 58 : S375 - S375
  • [40] RVD with weekly subcutaneous bortezomib minimizes neuropathy and maintains efficacy in a diverse multiple myeloma cohort
    Gill, Amitoj
    Jayswal, Rani
    Weiss, Heidi
    Rhodes, Jill
    Hegazi, Mohamed
    Herzig, Geoffrey
    Herzig, Roger
    Krem, Maxwell
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E210 - E210
12345